Medrad, Inc. Announces Launch of VirtualCARE(R) Remote Services Solution for Intego(TM) PET Infusion System
11/29/2010 11:41:43 AM
WARRENDALE, Pa., Nov. 29, 2010 /PRNewswire/ -- MEDRAD, Inc. a business of Bayer HealthCare, today announces the U.S. launch of VirtualCARE®, for the MEDRAD Intego PET Infusion System. VirtualCARE is a technology platform that allows MEDRAD to remotely support maintenance and system updates securely over the internet.
(Logo: http://photos.prnewswire.com/prnh/20040309/MEDRADLOGO )
MEDRAD is the first company in the U.S. to offer remote service and system support for an injection or infusion system. Utilizing advanced encryption technology, MEDRAD can now provide remote troubleshooting capabilities and system updates for Intego through VirtualCARE. The VirtualCARE solution has been designed for high performance and security at every level of its architecture, offering customers the potential for faster response time and reduced downtime.
VirtualCARE comes to the market two years after the launch of MEDRAD's Intego. Since its release in 2008, Intego has been placed in hospitals and clinics throughout the U.S., Europe, Australia and the Middle East. The Intego system is loaded with a multi-dose vial of 18F-FDG or 18F-NaF and nuclear medicine technologists can dose on demand from a touchscreen to enable precise, flexible, safe, and efficient administration of the radiopharmaceutical. VirtualCARE is the next step for MEDRAD to enhance service and support capabilities for the Intego PET Infusion System.
"MEDRAD is excited to offer the VirtualCARE technology to support one of our newest and quickly growing platforms with this initial launch for Intego," said Diane Watson, executive director of service commercialization for MEDRAD. "We are also looking to the future when the VirtualCARE technology can be utilized to support other MEDRAD product platforms in Radiology and Cardiology around the world."
About MEDRAD, Inc.
MEDRAD, Inc. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer HealthCare. More company information is available at www.medrad.com.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
SOURCE MEDRAD, Inc.